J&J’s AKEEGA Wins EU Approval for mHSPC – PARP/Abiraterone Combo Expands to Earlier-Line Prostate Cancer

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved a new indication for AKEEGA (niraparib and abiraterone acetate dual-action tablet) for metastatic hormone-sensitive prostate cancer (mHSPC) patients with BRCA1/2 mutations (germline and/or somatic), to be used in combination with prednisone/prednisolone (AAP) and androgen deprivation therapy (ADT). The approval expands AKEEGA from its April 2023 mCRPC indication to first-line mHSPC, capturing the largest addressable prostate cancer population with a dual-mechanism targeted therapy addressing both androgen receptor axis and BRCA1/2-driven tumor vulnerabilities.

Regulatory Milestone

Drug Profile & Dual-Mechanism Rationale

Synergy in BRCA1/2-mutant mHSPC:

• Androgen deprivation: Foundation of mHSPC treatment
• PARP inhibition: Exploits DNA repair deficiency in BRCA-mutant clones emerging under ADT pressure
• Early Intervention: Prevents castration resistance development; prolongs hormone-sensitive period

Clinical & Commercial Impact

Competitive Landscape

Regulatory Timeline & Launch Execution

Forward‑Looking Statements
This brief contains forward‑looking statements regarding commercial launch performance, U.S. regulatory expansion, and competitive positioning for AKEEGA in mHSPC. Actual results may differ due to reimbursement negotiations, BRCA testing adoption rates, and competitive dynamics with PARP inhibitor combinations.-Fineline Info & Tech